Research Article
EMMPRIN Expression in Oral Squamous Cell Carcinomas: Correlation with Tumor Proliferation and Patient Survival
Table 1
Clinicopathological characteristics of the 74 patients with OSCC and their association with EMMPRIN and Ki-67 expressions.
| | Factor | (%) | EMMPRIN overexpression | Ki-67 high expression | | (%) | value | (%) | value |
| | All cases | 74 (100%) | 56 (75.7%) | | 38 (51.4%) | | | Gender | | | | | | | Female | 19 (25.7%) | 11 (63.2%) | 0.140 | 8 (42.1%) | 0.350 | | Male | 55 (74.3%) | 44 (80%) | 30 (54.5%) | | Age | | | | | | | <62 years | 37 (50%) | 30 (81.1%) | 0.278 | 22 (59.5%) | 0.163 | | ≥62 years | 37 (50%) | 26 (70.3%) | 16 (43.2%) | | Location | | | | | | | Labial mucosa | 7 (9.5%) | 6 (85.7%) | 0.430 | 1 (14.3%) | 0.396 | | Floor of the mouth | 10 (13.5%) | 7 (70%) | 8 (80%) | | Tongue | 24 (32.4%) | 15 (62.5%) | 13 (54.2%) | | Buccal mucosa | 5 (6.8%) | 5 (100%) | 2 (40%) | | Retromolar trigone | 11 (14.9%) | 8 (72.7%) | 5 (45.5%) | | Hard palate | 9 (12.2%) | 8 (88.9%) | 3 (55.6%) | | Gingiva | 8 (10.8%) | 7 (87.5%) | 4 (50%) | | Tumor size | | | | | | | T1 | 13 (17.6%) | 8 (61.5%) | 0.132 | 6 (46.2%) | 0.396 | | T2 | 29 (39.2%) | 20 (69%) | 12 (41.4%) | | T3 | 9 (12.2%) | 9 (100%) | 6 (66.7%) | | T4 | 23 (31%) | 19 (82.6%) | 14 (60.9%) | | N status | | | | | | | N0 | 41 (55.4%) | 28 (68.3%) | 0.349 | 16 (39%) | 0.052 | | N1 | 12 (16.2%) | 11 (91.7%) | 7 (58.3%) | | N2 | 17 (23%) | 14 (82.4%) | 11 (64.7%) | | N3 | 4 (5.4%) | 3 (75%) | 4 (100%) | | Stage | | | | | | | I | 12 (16.2%) | 8 (66.7%) | 0.064 | 6 (50%) | 0.080 | | II | 23 (31.1%) | 14 (60.9%) | 7 (30.4%) | | III | 10 (13.5%) | 10 (100%) | 7 (70%) | | IV | 29 (39.2%) | 24 (82.8%) | 18 (62.1%) | | Treatment modality | | | | | | | SG | 28 (37.8%) | 20 (71.4%) | 0.633 | 12 (42.9%) | 0.522 | | SG + RT | 23 (31.3%) | 17 (73.9%) | 13 (56.5%) | | CT + SG or RCT | 23 (31.3%) | 19 (82.6%) | 13 (56.5%) | | Tumor grade | | | | | | | G1 | 42 (56.8%) | 26 (61.9%) | 0.002 | 16 (38.1%) | 0.009 | | G2 + G3 | 32 (43.2%) | 30 (93.8%) | 22 (68.8%) | | Margin status* | | | | | | | Free of tumor | 33 (57.9%) | 23 (69.7%) | 0.423 | 14 (42.4%) | 0.236 | | With tumor | 24 (42.1%) | 19 (79.2%) | 14 (58.3%) | | Perineural permeation | | | | | | | Absent | 66 (89.2%) | 50 (75.8%) | 0.962 | 33 (50%) | 0.504 | | Present | 8 (10.8%) | 6 (75%) | 5 (62.5%) | | Lymphatic invasion | | | | | | | Absent | 58 (78.4%) | 46 (79.3%) | 0.165 | 30 (51.7%) | 0.903 | | Present | 16 (21.6%) | 10 (62.5%) | 8 (50%) |
|
|
SG: surgery; RT: radiotherapy; CT: chemotherapy; RCT: radiochemotherapy.
Not determined in the 17 cases.
|
